已收盘 09-19 16:00:00
0.000
0.00%
Esperion announced that its partner, Otsuka Pharmaceutical, has received approval in Japan to market NEXLETOL for hypercholesterolemia and familial hypercholesterolemia. This marks a major milestone in Esperion's international growth strategy, as Japan is one of the top three global markets for cardiovascular prevention. With NEXLETOL now approved in the U.S., Europe, and Japan, Esperion has expanded access to its non-statin LDL-C lowering therap...
09-19 12:00
又一家企业撤离港股。 8月29日下午4时,随着香港联交所上市地位的正式撤销,北京建设(控股)有限公司走完了它作为上市公司的最后一段旅程。 这家背靠北控集团、一度...
09-02 16:52